Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp alfa in esophageal squamous cell carcinoma
NCT04481256Recruiting
- Sponsor
- University of Amsterdam
- Start
- Nov 2020
- Primary completion
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of bintrafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by University of Amsterdam. Primary endpoint: Feasibility difined as the percentage of patients completing at least two cycles of bintrafusp alfa at 36 months. Started Nov 2020; status: recruiting.
02
Drugs
bintrafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04481256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481256.